Prediction of non-sentinel node status and outcome in sentinel node-positive melanoma patients

European Journal of Surgical Oncology

Volumn 34, Issue 1, 2008, Pages 82-88

  Roka, F ^a   Mastan, P ^a   Binder, M ^a   Okamoto, I ^a   Mittlboeck, M ^a   Horvat, R ^a   Pehamberger, H ^a   Diem, E ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Completion lymph node dissection; Melanoma; Non sentinel lymph node

Indexed keywords

ADULT; AGED; ALGORITHM; ANALYTICAL PARAMETERS; ARTICLE; CANCER MORTALITY; CANCER RECURRENCE; CANCER RISK; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ASSESSMENT; CLINICAL FEATURE; COMPARATIVE STUDY; CORRELATION ANALYSIS; DISEASE FREE SURVIVAL; DISEASE SEVERITY; FEMALE; FOLLOW UP; GENDER; GROUPS BY AGE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; KAPLAN MEIER METHOD; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MELANOMA; PATHOLOGICAL ANATOMY; PATHOLOGY; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; SCORING SYSTEM; SENTINEL LYMPH NODE; SENTINEL LYMPH NODE BIOPSY; STATISTICAL SIGNIFICANCE; TUMOR VOLUME; ULCER; UNIVARIATE ANALYSIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALGORITHMS; HUMANS; KAPLAN-MEIERS ESTIMATE; LYMPH NODES; LYMPHATIC METASTASIS; MELANOMA; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; TREATMENT OUTCOME;

EID: 37349001713     PISSN: 07487983     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejso.2007.01.027     Document Type: Article

References (33)

1. Gershenwald J.E., Thompson W., Mansfield P.F., et al. Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol 17 3 (1999) 976-983
2. Vuylsteke R.J., van Leeuwen P.A., Statius Muller M.G., et al. Clinical outcome of stage I/II melanoma patients after selective sentinel lymph node dissection: long-term follow-up results. J Clin Oncol 21 6 (2003) 1057-1065
3. Balch C.M., Soong S.J., Gershenwald J.E., et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 19 16 (2001) 3622-3634
4. McMasters K.M., Wong S.L., Edwards M.J., et al. Frequency of nonsentinel lymph node metastasis in melanoma. Ann Surg Oncol 9 2 (2002) 137-141
5. Wagner J.D., Gordon M.S., Chuang T.Y., et al. Predicting sentinel and residual lymph node basin disease after sentinel lymph node biopsy for melanoma. Cancer 89 2 (2000) 453-462
6. Starz H., Balda B.R., Kramer K.U., et al. A micromorphometry-based concept for routine classification of sentinel lymph node metastases and its clinical relevance for patients with melanoma. Cancer 91 11 (2001) 2110-2121
7. Dewar D.J., Newell B., Green M.A., et al. The microanatomic location of metastatic melanoma in sentinel lymph nodes predicts nonsentinel lymph node involvement. J Clin Oncol 22 16 (2004) 3345-3349
8. Reeves M.E., Delgado R., Busam K.J., et al. Prediction of nonsentinel lymph node status in melanoma. Ann Surg Oncol 10 1 (2003) 27-31
9. Cochran A.J., Wen D.R., Huang R.R., et al. Prediction of metastatic melanoma in nonsentinel nodes and clinical outcome based on the primary melanoma and the sentinel node. Mod Pathol 17 7 (2004) 747-755
10. Kirkwood J.M., Strawderman M.H., Ernstoff M.S., et al. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 14 1 (1996) 7-17
11. Berger D.H., Feig B.W., Podoloff D., et al. Lymphoscintigraphy as a predictor of lymphatic drainage from cutaneous melanoma. Ann Surg Oncol 4 3 (1997) 247-251
12. Cascinelli N., Belli F., Santinami M., et al. Sentinel lymph node biopsy in cutaneous melanoma: the WHO Melanoma Program experience. Ann Surg Oncol 7 (2000) 469-474
13. Gutzmer R., Al Ghazal M., Geerlings H., et al. Sentinel node biopsy in melanoma delays recurrence but does not change melanoma-related survival: a retrospective analysis of 673 patients. Br J Dermatol 153 6 (2005) 1137-1141
14. Morton D.L., Thompson J.F., Cochran A.J., et al., (MSLT Group). Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med 355 13 (2006) 1307-1317
15. Veronesi U., Adamus J., Bandiera D.C., et al. Delayed regional lymph node dissection in stage I melanoma of the skin of the lower extremities. Cancer 49 (1982) 2420-2430
16. Balch C.M., Soong S., Ross M.I., et al. Long-term results of a multi-institutional randomized trial comparing prognostic factors and surgical results for intermediate thickness melanomas (1.0 to 4.0 mm). Intergroup Melanoma Surgical Trial. Ann Surg Oncol 7 2 (2000) 87-97
17. Cascinelli N., Morabito A., Santinami M., et al. Immediate or delayed dissection of regional nodes in patients with melanoma of the trunk: a randomised trial. WHO Melanoma Programme. Lancet 351 (1998) 793-796
18. Morton D.L., Wen D.-R., Wong J.H., et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 127 (1992) 392-399
19. Reintgen D., Cruse C.W., Berman C., et al. The orderly progression of melanoma nodal metastases. Ann Surg 220 (1994) 759-767
20. Thompson J.F., McCarthy W.H., Bosch C.M.J., et al. Sentinel lymph node status as an indicator of the presence of metastatic melanoma in regional lymph nodes. Melanoma Res 5 (1995) 255-260
21. Zogakis T.G., Essner R., Wang H.J., et al. Melanoma recurrence patterns after negative sentinel lymphadenectomy. Arch Surg 140 9 (2005) 865-871
22. Roka F., Kittler H., Cauzig P., et al. Sentinel node status in melanoma patients is not predictive for overall survival upon multivariate analysis. Br J Cancer 92 4 (2005) 662-667
23. Paek S.C., Griffith K.A., Johnson T.M., et al. The impact of factors beyond Breslow depth on predicting sentinel lymph node positivity in melanoma. Cancer 109 1 (2007) 100-108
24. Kruper L.L., Spitz F.R., Czerniecki B.J., et al. Predicting sentinel node status in AJCC stage I/II primary cutaneous melanoma. Cancer 107 10 (2006) 2436-2445
25. Azzola M.F., Shaw H.M., Thompson J.F., et al. Tumor mitotic rate is a more powerful prognostic indicator than ulceration in patients with primary cutaneous melanoma: an analysis of 3661 patients from a single center. Cancer 97 6 (2003) 1488-1498
26. Gietema H.A., Vuylsteke R.J., van Diest P.J., et al. Predicting nonsentinel lymph node involvement in stage I/II melanoma. Ann Surg Oncol 10 8 (2003) 993
27. Scolyer R.A., Li L.X., McCarthy S.W., et al. Micromorphometric features of positive sentinel lymph nodes predict involvement of nonsentinel nodes in patients with melanoma. Am J Clin Pathol 122 4 (2004) 532-539
28. Vuylsteke R.J., Borgstein P.J., van Leeuwen P.A., et al. Sentinel lymph node tumor load: an independent predictor of additional lymph node involvement and survival in melanoma. Ann Surg Oncol 12 6 (2005) 440-448
29. Ranieri J.M., Wagner J.D., Azuaje R., et al. Prognostic importance of lymph node tumor burden in melanoma patients staged by sentinel node biopsy. Ann Surg Oncol 9 10 (2002) 975-981
30. Carlson G.W., Murray D.R., Lyles R.H., et al. The amount of metastatic melanoma in a sentinel lymph node: does it have prognostic significance?. Ann Surg Oncol 10 5 (2003) 575-581
31. Sabel M.S., Griffith K., Sondak V.K., et al. Predictors of nonsentinel lymph node positivity in patients with a positive sentinel node for melanoma. J Am Coll Surg 201 1 (2005) 37-47
32. Lee J.H., Essner R., Torisu-Itakura H., et al. Factors predictive of tumor-positive nonsentinel lymph nodes after tumor-positive sentinel lymph node dissection for melanoma. J Clin Oncol 22 18 (2004) 3677-3684
33. Salti G.I., and Das Gupta T.K. Predicting residual lymph node basin disease in melanoma patients with sentinel lymph node metastases. Am J Surg 186 2 (2003) 98-101